Unity Biotechnology (LTS:0YC0) Other Financing: $0.00 Mil (TTM As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0YC0 Unity Biotechnology Inc LTS:0YC0
25 GF Score
Price $0.06
View Full Analysis

What is Unity Biotechnology Other Financing?

Unity Biotechnology LTS:0YC0 25 Other Financing is $0.00 Mil as of Mar. 2025. GuruFocus rates LTS:0YC0 with a GF Score™ of 25/100.

Unity Biotechnology's Other Financing for the three months ended in Mar. 2025 was $0.00 Mil.

Unity Biotechnology's Other Financing for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil.

Unity Biotechnology Other Financing Historical Data

* Premium members only.

The historical data trend for Unity Biotechnology's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Unity Biotechnology Other Financing Chart

Unity Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Financing
Get a 7-Day Free Trial Premium Member Only 2.46 2.34 -1.83 -1.45 0.00

Unity Biotechnology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0YC0
25GF Score
Unity Biotechnology Inc LTS:0YC0
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Unity Biotechnology Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $0.00 Mil mean?
Unity Biotechnology (LTS:0YC0) has a Other Financing of $0.00 Mil as of Mar. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Unity Biotechnology and its competitors.
Is Unity Biotechnology's Other Financing too high?
Unity Biotechnology's current Other Financing is $0.00 Mil. Overall, Unity Biotechnology has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Unity Biotechnology's Other Financing compare to ADTX and HEPA?
Unity Biotechnology's Other Financing of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Unity Biotechnology and its competitors. Unity Biotechnology's current Other Financing is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unity Biotechnology stock overvalued right now?
Unity Biotechnology (LTS:0YC0) has a current Other Financing of $0.00 Mil. The current Other Financing is $0.00 Mil. Unity Biotechnology's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Unity Biotechnology (LTS:0YC0), the current Other Financing is $0.00 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Unity Biotechnology Business Description

Address 285 East Grand Avenue, South San Francisco, CA, USA, 94080
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
25GF Score

Get the complete analysis for LTS:0YC0

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.06
Price